Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT04588922 is registered in ClinicalTrials.gov with Sellas Life Sciences Group as lead sponsor.

NCT NCT04588922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04588922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML
Lead sponsor
Sellas Life Sciences Group
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 10, 2021
Completion date
December 31, 2027
Enrollment
160 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies